IMBiologics, Nexi, Xymedi, AimedBio, Ezcuris, and Sungkyunkwan University Selected for 6 Projects

On the 10th, the Korea Drug Development Fund (KDDF) revealed the results of its "2024 National New Drug Development Program Outstanding Project Presentation" held at Hotel Naroo Seoul M Gallery. A total of 391 projects were evaluated, and six were selected as outstanding.

The six outstanding projects selected by the KDDF include:

• IMBiologics: Development of an autoimmune disease treatment with multi-immunomodulatory functions
• Nex-I: Research on lead antibodies targeting immune checkpoint inhibitor resistance factors
• Aimedbio: Non-clinical development of FGFR3 ADC for bladder cancer and brain tumor treatment
• Sungkyunkwan University: Development of a treatment for EYS-related retinal pigment epithelium disease using prime editor
• Zymedi: Phase 1 clinical trial of a pulmonary arterial hypertension treatment that inhibits immune cell migration
• Azcuris: Discovery of novel small-molecule inhibitors targeting IL-33 cytokines

Similar to last year, the KDDF categorized the six projects into three areas:

• High Performance: IMBiologics, Nex-I, Aimedbio
• Technology Breakthrough: Zymedi, Sungkyunkwan University
• New Insight: Zymedi (overlap), Azcuris

Source: Shin Changmin, Reporter (changmin.shin@bios.co.kr)